A book featuring all inventions available for license from L2C Partners institutions.
Braftide is a synthetic peptide inhibitor that works via a novel dual mechanism of action to inhibit BRAF, a protein that is responsible for cell proliferation, differentiation, and migration. This protein is an integral part of the MAP kinase / ERK signaling pathway. Mutations in BRAF have been identified in melanoma, colorectal cancer, non-Hodgkins lymphoma, […]
The University of the Sciences research team has uncovered CAPER as a novel therapeutic target inside breast cancer cells. CAPER has been shown to be overexpressed in these cancer cells and seems to be helping the cancer thrive and survive. Targeted cancer therapy is becoming a leading approach to cancer treatment and Dr. Jasmin and […]
The Glucagon-Like Peptide 1 Receptor (GLP-1R), a member of Class B family of G-protein coupled receptors (GPCRs), is an effective target for the treatment of type-2 diabetes, and its incretin peptide and varied peptide mimetics are adopted drugs. Despite remarkable anti-diabetic effects, GLP-1R peptide-based agonists are limited by several disadvantages. Although considerable progress has been […]
Lead University of the Sciences Inventor Clyde M. Ofner III, Ph.D Unmet Need A major challenge in cancer chemotherapy is the selective delivery of small molecule anti-cancer agents to cancer cells. Doxorubicin (DOX) is a potent antineoplastic agent that is effective against a wide range of solid tumors and lymphomas but it is also associated […]